Go Pro
→ Louis Navellier: My #1 AI stock for 2026 (name & ticker inside) (From InvestorPlace) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
$33.83
+3.6%		$35.85
$22.24
▼
$46.00
$2.02B0.581.06 million shs272,020 shs
CG Oncology, Inc. stock logo
CGON
CG Oncology
$78.90
+0.9%		$71.69
$25.25
▼
$80.97
$6.99B0.231.13 million shs235,837 shs
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
$102.33
-0.1%		$92.49
$14.34
▼
$115.51
$6.78B-0.341.12 million shs241,987 shs
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
$112.96
+1.4%		$108.47
$74.50
▼
$122.20
$7.74B1.92775,526 shs106,750 shs
(Almost) Everything You Need To Know About The EV Market Cover
(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
-1.36%-2.94%-10.23%+15.21%-15.88%
CG Oncology, Inc. stock logo
CGON
CG Oncology
-1.98%+1.45%+12.85%+26.40%+190.60%
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
-5.13%-9.09%+11.13%+73.42%+563.34%
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
+1.31%-3.47%+9.15%+24.07%+7.91%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
$33.83
+3.6%		$35.85
$22.24
▼
$46.00
$2.02B0.581.06 million shs272,020 shs
CG Oncology, Inc. stock logo
CGON
CG Oncology
$78.90
+0.9%		$71.69
$25.25
▼
$80.97
$6.99B0.231.13 million shs235,837 shs
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
$102.33
-0.1%		$92.49
$14.34
▼
$115.51
$6.78B-0.341.12 million shs241,987 shs
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
$112.96
+1.4%		$108.47
$74.50
▼
$122.20
$7.74B1.92775,526 shs106,750 shs
(Almost) Everything You Need To Know About The EV Market Cover
(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
-1.36%-2.94%-10.23%+15.21%-15.88%
CG Oncology, Inc. stock logo
CGON
CG Oncology
-1.98%+1.45%+12.85%+26.40%+190.60%
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
-5.13%-9.09%+11.13%+73.42%+563.34%
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
+1.31%-3.47%+9.15%+24.07%+7.91%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
2.55
Moderate Buy$41.2520.85% Upside
CG Oncology, Inc. stock logo
CGON
CG Oncology
2.71
Moderate Buy$83.185.56% Upside
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
2.82
Moderate Buy$134.3028.70% Upside
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
2.78
Moderate Buy$142.4425.42% Upside

Current Analyst Ratings Breakdown

Latest AGIO, RYTM, ORKA, and CGON Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/24/2026
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy
8/11/2026
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$200.00
8/11/2026
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
Wedbush logo
Wedbush
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform$165.00
8/11/2026
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
BTIG Research logo
BTIG Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$151.00
8/7/2026
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
JPMorgan Chase & Co. logo
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetNeutral$31.00 ➝ $34.00
8/7/2026
CG Oncology, Inc. stock logo
CGON
CG Oncology
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOutperform$81.00 ➝ $79.00
8/7/2026
CG Oncology, Inc. stock logo
CGON
CG Oncology
Piper Sandler logo
Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$82.00 ➝ $85.00
8/7/2026
CG Oncology, Inc. stock logo
CGON
CG Oncology
Truist Financial Corporation logo
Truist Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$82.00 ➝ $85.00
8/7/2026
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
JPMorgan Chase & Co. logo
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$145.00 ➝ $146.00
8/5/2026
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
Canaccord Genuity Group Inc. logo
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$154.00
8/5/2026
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingMarket Outperform
(Data available from 8/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
$98.34M20.72N/AN/A$20.46 per share1.67
CG Oncology, Inc. stock logo
CGON
CG Oncology
$4.04M1,728.92N/AN/A$9.33 per share8.45
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
N/AN/AN/AN/A$9.69 per shareN/A
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
$189.76M41.02N/AN/A$2.08 per share54.60
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
-$412.78M-$7.01N/AN/AN/A-418.24%-35.67%-33.06%10/29/2026 (Estimated)
CG Oncology, Inc. stock logo
CGON
CG Oncology
-$160.99M-$2.69N/AN/AN/A-3,602.68%-25.20%-23.98%11/13/2026 (Estimated)
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
-$105.43M-$2.03N/AN/AN/AN/A-21.65%-20.88%11/11/2026 (Estimated)
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
-$196.54M-$3.11N/AN/AN/A-85.59%-159.87%-44.00%11/3/2026 (Estimated)

Latest AGIO, RYTM, ORKA, and CGON Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/10/2026Q2 2026
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
-$0.5125-$0.55-$0.0375-$0.55N/AN/A
8/6/2026Q2 2026
CG Oncology, Inc. stock logo
CGON
CG Oncology
-$0.6642-$0.90-$0.2359-$0.90$0.36 million$1.16 million
8/4/2026Q2 2026
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
-$0.8072-$0.73+$0.0772-$0.73$67.66 million$71.26 million
7/30/2026Q2 2026
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
-$1.65-$1.69-$0.04-$1.69$26.40 million$44.75 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
N/AN/AN/AN/AN/A
CG Oncology, Inc. stock logo
CGON
CG Oncology
N/AN/AN/AN/AN/A
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
N/AN/AN/AN/AN/A
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
N/A
10.22
9.79
CG Oncology, Inc. stock logo
CGON
CG Oncology
N/A
22.22
22.20
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
N/A
38.51
38.51
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
N/A
3.45
3.20

Institutional Ownership

CompanyInstitutional Ownership
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
N/A
CG Oncology, Inc. stock logo
CGON
CG Oncology
26.56%
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
56.44%
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
N/A

Insider Ownership

CompanyInsider Ownership
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
5.40%
CG Oncology, Inc. stock logo
CGON
CG Oncology
4.80%
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
23.49%
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
5.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
39059.70 million56.48 millionOptionable
CG Oncology, Inc. stock logo
CGON
CG Oncology
6188.64 million84.39 millionOptionable
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
N/A66.21 million50.66 millionN/A
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
14068.53 million64.49 millionOptionable

Recent News About These Companies

Nicholas Investment Partners LP Makes New $15.46 Million Investment in Rhythm Pharmaceuticals, Inc. $RYTM
August 25 at 6:32 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-nicholas-investment-partners-lp-makes-new-1546-million-investment-in-rhythm-pharmaceuticals-inc-rytm-2026-08-25/
Nan Fung Group Holdings Ltd Purchases New Position in Rhythm Pharmaceuticals, Inc. $RYTM
August 25 at 5:51 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-nan-fung-group-holdings-ltd-purchases-new-position-in-rhythm-pharmaceuticals-inc-rytm-2026-08-25/
Rhythm Pharmaceuticals Receives Japan Approval for Imcivree
August 24 at 6:11 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/rhythm-pharmaceuticals-receives-japan-approval-124306508.html
Rhythm Pharmaceuticals Announces MHLW Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity (HO) in Japan
August 24 at 8:00 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/24/3349657/0/en/rhythm-pharmaceuticals-announces-mhlw-approval-of-imcivree-setmelanotide-for-patients-with-acquired-hypothalamic-obesity-ho-in-japan.html
6,156,902 Shares in Rhythm Pharmaceuticals, Inc. $RYTM Purchased by BlackRock Inc.
August 24 at 3:35 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-6156902-shares-in-rhythm-pharmaceuticals-inc-rytm-purchased-by-blackrock-inc-2026-08-24/
Eli Lilly and Novo Nordisk Can't Treat This Form of Obesity. Billionaire Stanley Druckenmiller Is Betting Rhythm Pharmaceuticals Can
August 23 at 6:00 PM  |  fool.comhttps://www.fool.com/investing/2026/08/23/eli-lilly-and-novo-nordisk-cant-treat-this-form-of/
Deutsche Bank AG Purchases New Position in Rhythm Pharmaceuticals, Inc. $RYTM
August 23 at 3:43 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-deutsche-bank-ag-purchases-new-position-in-rhythm-pharmaceuticals-inc-rytm-2026-08-23/
Blue Owl Capital Holdings LP Invests $6.82 Million in Rhythm Pharmaceuticals, Inc. $RYTM
August 21, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-blue-owl-capital-holdings-lp-invests-682-million-in-rhythm-pharmaceuticals-inc-rytm-2026-08-21/
Rhythm Pharmaceuticals: Building A Defensive MC4R Franchise
August 18, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4937599-rhythm-pharmaceuticals-building-a-defensive-mc4r-franchise
Rhythm Pharmaceuticals (NASDAQ:RYTM) Insider Joseph Shulman Sells 5,079 Shares
August 18, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-rytm-insider-buying-and-selling-2026-08-18/
Insider Selling: Rhythm Pharmaceuticals (NASDAQ:RYTM) Insider Sells 5,079 Shares of Stock
August 17, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-selling-rhythm-pharmaceuticals-nasdaqrytm-insider-sells-5079-shares-of-stock-2026-08-17/
Rhythm Pharmaceuticals (NASDAQ:RYTM) Insider Alastair Garfield Sells 7,763 Shares
August 17, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/rhythm-pharmaceuticals-nasdaqrytm-insider-alastair-garfield-sells-7763-shares-2026-08-17/
Rhythm Pharmaceuticals Announces Appointment of Manher (AJ) Joshi as Chief Medical Officer
August 17, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/17/3346041/0/en/rhythm-pharmaceuticals-announces-appointment-of-manher-aj-joshi-as-chief-medical-officer.html
Rhythm Pharmaceuticals Eyes AHO Growth, Global IMCIVREE Expansion and Pipeline Catalysts
August 17, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/rhythm-pharmaceuticals-eyes-aho-growth-global-imcivree-expansion-and-pipeline-catalysts-2026-08-17/
Jennifer Kayden Lee Sells 75,834 Shares of Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock
August 16, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30964891
Yann Mazabraud Sells 57,000 Shares of Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock
August 16, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30964751
Rhythm Pharmaceuticals (NASDAQ:RYTM) EVP Yann Mazabraud Sells 57,000 Shares of Stock
August 15, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-rytm-insider-buying-and-selling-2026-08-15/
Rhythm Pharmaceuticals (NASDAQ:RYTM) EVP Yann Mazabraud Sells 57,000 Shares
August 14, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/rhythm-pharmaceuticals-nasdaqrytm-evp-yann-mazabraud-sells-57000-shares-2026-08-14/
Insider Selling: Rhythm Pharmaceuticals (NASDAQ:RYTM) EVP Sells 75,834 Shares of Stock
August 14, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-selling-rhythm-pharmaceuticals-nasdaqrytm-evp-sells-75834-shares-of-stock-2026-08-14/
Dimensional Fund Advisors LP Sells 12,867 Shares of Rhythm Pharmaceuticals, Inc. $RYTM
August 14, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-dimensional-fund-advisors-lp-sells-12867-shares-of-rhythm-pharmaceuticals-inc-rytm-2026-08-14/
Why Is Rhythm Pharmaceuticals Stock Trading Higher On Wednesday?
August 12, 2026  |  benzinga.comhttps://www.benzinga.com/markets/biotech/26/08/61152014/why-is-rhythm-pharmaceuticals-stock-trading-higher-on-wednesday?utm_source=snapi

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
AMD logo on a glowing processor chip with red circuit traces, highlighting AI and data-center semiconductor demand.
AMD’s AI Bubble Could Burst Into Explosive Upside
By Thomas Hughes | July 27, 2026
SpaceX logo beside a rocket on a launch pad at sunset, with a colorful sky in the background.
SpaceX’s First Earnings Report Could Decide Whether Shorts or Bulls Have Control
By Jeffrey Neal Johnson | August 3, 2026
Laboratory with a cryogenic quantum processor chamber, optical laser setup on a table, and data monitors displaying waveforms.
Quantum Earnings Week: Winners and Losers Are Finally Emerging
By Nathan Reiff | August 8, 2026
SoundHound AI logo displayed within a glowing orange ring against a dark background with light wave effects.
SoundHound AI Sends a Loud Signal After Its Q2 Earnings Beat
By Thomas Hughes | August 10, 2026
NVIDIA and OpenAI logos displayed on a computer chip against a background of data center servers.
NVIDIA’s OpenAI Backstop Puts AI Financing Risk in Focus
By Jeffrey Neal Johnson | July 29, 2026
Agios Pharmaceuticals stock logo

Agios Pharmaceuticals NASDAQ:AGIO

$33.83 +1.19 (+3.65%)
As of 12:54 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

CG Oncology stock logo

CG Oncology NASDAQ:CGON

$78.90 +0.67 (+0.86%)
As of 12:54 PM Eastern
This is a fair market value price provided by Massive. Learn more.

CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.

Oruka Therapeutics stock logo

Oruka Therapeutics NASDAQ:ORKA

$102.33 -0.09 (-0.09%)
As of 12:55 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.

Rhythm Pharmaceuticals stock logo

Rhythm Pharmaceuticals NASDAQ:RYTM

$112.96 +1.52 (+1.36%)
As of 12:54 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas